Synopsis
Synopsis
0
JDMF
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Bibr 1048
2. Dabigatran
3. Dabigatran Etexilate
4. Dabigatran Etexilate Mesylate
5. Etexilate Mesylate, Dabigatran
6. Etexilate, Dabigatran
7. Mesylate, Dabigatran Etexilate
8. N-((2-(((4-(aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1h-benzimidazol-5-yl)carbonyl)-n-2-pyridinyl-beta-alanine
9. Pradaxa
1. Dabigatran Etexilate Mesylate
2. 872728-81-9
3. Pradaxa
4. Ethyl 3-[[2-[[4-[(z)-n'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate;methanesulfonic Acid
5. Dtxsid20236248
6. Ex-a1966
7. Mfcd25424070
8. S5960
9. Ccg-213236
10. Cs-w004358
11. (z)-ethyl 3-(2-(((4-(n'-((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-n-(pyridin-2-yl)-1h-benzo[d]imidazole-5-carboxamido)propanoate Methanesulfonate
12. 728p819
| Molecular Weight | 723.8 g/mol |
|---|---|
| Molecular Formula | C35H45N7O8S |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 17 |
| Exact Mass | 723.30503259 g/mol |
| Monoisotopic Mass | 723.30503259 g/mol |
| Topological Polar Surface Area | 217 Ų |
| Heavy Atom Count | 51 |
| Formal Charge | 0 |
| Complexity | 1100 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Pradaxa |
| PubMed Health | Dabigatran (By mouth) |
| Drug Classes | Anticoagulant |
| Drug Label | The chemical name for dabigatran etexilate mesylate, a direct thrombin inhibitor, is -Alanine, N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl] phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-,ethyl ester, methanesulfo... |
| Active Ingredient | Dabigatran etexilate mesylate |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | eq 150mg base; eq 75mg base |
| Market Status | Prescription |
| Company | Boehringer Ingelheim |
| 2 of 2 | |
|---|---|
| Drug Name | Pradaxa |
| PubMed Health | Dabigatran (By mouth) |
| Drug Classes | Anticoagulant |
| Drug Label | The chemical name for dabigatran etexilate mesylate, a direct thrombin inhibitor, is -Alanine, N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl] phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-,ethyl ester, methanesulfo... |
| Active Ingredient | Dabigatran etexilate mesylate |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | eq 150mg base; eq 75mg base |
| Market Status | Prescription |
| Company | Boehringer Ingelheim |
Pradaxa 75 mg
- Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.
Pradaxa 110 mg
- Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.
- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age 75 years; heart failure (NYHA Class II); diabetes mellitus; hypertension.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
Pradaxa 150 mg
- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age 75 years; heart failure (NYHA Class II); diabetes mellitus; hypertension.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
Antithrombins
Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins. (See all compounds classified as Antithrombins.)
B01AE07
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-07-07
Pay. Date : 2014-04-21
DMF Number : 27960
Submission : 2014-04-04
Status : Active
Type : II
Date of Issue : 2025-07-15
Valid Till : 2028-07-07
Written Confirmation Number : WC-0067
Address of the Firm :
NDC Package Code : 55111-963
Start Marketing Date : 2013-09-25
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Sangjin Trading Co., Ltd.
Registration Date : 2021-07-05
Registration Number : Su583-29-ND
Manufacturer Name : Dr. Reddy's Laboratories Limited
Manufacturer Address : CTD-VI, APIIC Industrial Estate, Pydhibeemavaram, Ranasthalam Mandal, Srikakulam District, Andhra Pradesh, 532 409, India
| Available Reg Filing : ASMF, CDMF |
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37633
Submission : 2022-10-31
Status : Active
Type : II
Date of Issue : 2024-04-03
Valid Till : 2027-01-21
Written Confirmation Number : WC-0493
Address of the Firm :
NDC Package Code : 42765-054
Start Marketing Date : 2023-01-24
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
Jinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28352
Submission : 2014-07-07
Status : Active
Type : II
Date of Issue : 2025-06-27
Valid Till : 2028-06-16
Written Confirmation Number : WC-0037
Address of the Firm :
NDC Package Code : 58032-2021
Start Marketing Date : 2014-05-19
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
| Available Reg Filing : ASMF |
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-07-15
Pay. Date : 2014-04-22
DMF Number : 28118
Submission : 2014-04-27
Status : Active
Type : II
Certificate Number : CEP 2024-114 - Rev 01
Issue Date : 2025-03-20
Type : Chemical
Substance Number : 3095
Status : Valid
Date of Issue : 2025-06-04
Valid Till : 2028-05-20
Written Confirmation Number : WC-0001
Address of the Firm :
NDC Package Code : 15894-0025
Start Marketing Date : 2013-06-21
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (100kg/100kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Korea United Pharmaceutical Co., Ltd.
Registration Date : 2017-06-28
Registration Number : Su207-29-ND(1)
Manufacturer Name : Teva API India Pvt. LTD.
Manufacturer Address : Plot no. Q1 to Q4, Industrial Area, Ghirongi, Malanpur, Distt. Bhind M.P., India
| Available Reg Filing : ASMF |
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Dabigatran Etexilate Capsules (generic for Pradaxa®), is good at preventing blood clots that can cause a stroke or heart attack, but it can be very expensive and must be used carefully in patients with kidney problems.
Lead Product(s): Dabigatran Etexilate Mesylate,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Dabigatran Etexilate-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 22, 2022
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dabigatran Etexilate Mesylate,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dabigatran Etexilate Capsules (generic for Pradaxa®), is good at preventing blood clots that can cause a stroke or heart attack, but it can be very expensive and must be used carefully in patients with kidney problems.
Product Name : Dabigatran Etexilate-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 22, 2022
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
PF-08049820 is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Dermatitis, Atopic.
Lead Product(s): PF-08049820,Midazolam,Dabigatran Etexilate Mesylate,Ethinyl Estradiol,Levonorgestrel
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 24, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : PF-08049820,Midazolam,Dabigatran Etexilate Mesylate,Ethinyl Estradiol,Levonorgestrel
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PF-08049820 is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 24, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Dabigatran Etexilate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Dabigatran Etexilate Mesylate,BI1291583
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 24, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dabigatran Etexilate Mesylate,BI1291583
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dabigatran Etexilate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 24, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Dabigatran Etexilate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of COVID-19.
Lead Product(s): Dabigatran Etexilate Mesylate,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 18, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dabigatran Etexilate Mesylate,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dabigatran Etexilate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 18, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Dabigatran etexilate mesylate is an approved direct thrombin inhibitor, which is indicated for deep vein thrombosis and pulmonary embolism.
Lead Product(s): Dabigatran Etexilate Mesylate,Inapplicable
Therapeutic Area: Hematology Brand Name: Pradaxa-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 13, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dabigatran Etexilate Mesylate,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Alembic Gets USFDA Nod for Generic Medication
Details : Dabigatran etexilate mesylate is an approved direct thrombin inhibitor, which is indicated for deep vein thrombosis and pulmonary embolism.
Product Name : Pradaxa-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 13, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Zongertinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Zongertinib,Dabigatran Etexilate Mesylate,Rosuvastatin Calcium,Metformin,Furosemide
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 17, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zongertinib,Dabigatran Etexilate Mesylate,Rosuvastatin Calcium,Metformin,Furosemide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zongertinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 17, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Pradaxa-Generic (dabigatran etexilate) is a USFDA approved direct thrombin inhibitor, which is indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation.
Lead Product(s): Dabigatran Etexilate Mesylate,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Pradaxa-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 19, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dabigatran Etexilate Mesylate,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Alembic Pharmaceuticals gets USFDA final approval for Dabigatran Etexilate capsules
Details : Pradaxa-Generic (dabigatran etexilate) is a USFDA approved direct thrombin inhibitor, which is indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation.
Product Name : Pradaxa-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 19, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
BAY2927088 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Lead Product(s): Sevabertinib,Dabigatran Etexilate Mesylate,Rosuvastatin Calcium
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 26, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Sevabertinib,Dabigatran Etexilate Mesylate,Rosuvastatin Calcium
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BAY2927088 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 26, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Dabigatran Etexilate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Dabigatran Etexilate Mesylate,Lotiglipron
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 28, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Dabigatran Etexilate Mesylate,Lotiglipron
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dabigatran Etexilate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 28, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
ARV-471 is a PROTACs drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): ARV-471,Dabigatran Etexilate Mesylate
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: PROTACs
Sponsor: Arvinas
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 06, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ARV-471,Dabigatran Etexilate Mesylate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Arvinas
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ARV-471 is a PROTACs drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : PROTACs
Upfront Cash : Inapplicable
January 06, 2023

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
14
PharmaCompass offers a list of Dabigatran Etexilate Mesylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Dabigatran Etexilate Mesylate manufacturer or Dabigatran Etexilate Mesylate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dabigatran Etexilate Mesylate manufacturer or Dabigatran Etexilate Mesylate supplier.
PharmaCompass also assists you with knowing the Dabigatran Etexilate Mesylate API Price utilized in the formulation of products. Dabigatran Etexilate Mesylate API Price is not always fixed or binding as the Dabigatran Etexilate Mesylate Price is obtained through a variety of data sources. The Dabigatran Etexilate Mesylate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Dabigatran Etexilate Mesylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dabigatran Etexilate Mesylate, including repackagers and relabelers. The FDA regulates Dabigatran Etexilate Mesylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dabigatran Etexilate Mesylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Dabigatran Etexilate Mesylate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Dabigatran Etexilate Mesylate supplier is an individual or a company that provides Dabigatran Etexilate Mesylate active pharmaceutical ingredient (API) or Dabigatran Etexilate Mesylate finished formulations upon request. The Dabigatran Etexilate Mesylate suppliers may include Dabigatran Etexilate Mesylate API manufacturers, exporters, distributors and traders.
click here to find a list of Dabigatran Etexilate Mesylate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Dabigatran Etexilate Mesylate DMF (Drug Master File) is a document detailing the whole manufacturing process of Dabigatran Etexilate Mesylate active pharmaceutical ingredient (API) in detail. Different forms of Dabigatran Etexilate Mesylate DMFs exist exist since differing nations have different regulations, such as Dabigatran Etexilate Mesylate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Dabigatran Etexilate Mesylate DMF submitted to regulatory agencies in the US is known as a USDMF. Dabigatran Etexilate Mesylate USDMF includes data on Dabigatran Etexilate Mesylate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Dabigatran Etexilate Mesylate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Dabigatran Etexilate Mesylate suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Dabigatran Etexilate Mesylate Drug Master File in Korea (Dabigatran Etexilate Mesylate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Dabigatran Etexilate Mesylate. The MFDS reviews the Dabigatran Etexilate Mesylate KDMF as part of the drug registration process and uses the information provided in the Dabigatran Etexilate Mesylate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Dabigatran Etexilate Mesylate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Dabigatran Etexilate Mesylate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Dabigatran Etexilate Mesylate suppliers with KDMF on PharmaCompass.
A Dabigatran Etexilate Mesylate CEP of the European Pharmacopoeia monograph is often referred to as a Dabigatran Etexilate Mesylate Certificate of Suitability (COS). The purpose of a Dabigatran Etexilate Mesylate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Dabigatran Etexilate Mesylate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Dabigatran Etexilate Mesylate to their clients by showing that a Dabigatran Etexilate Mesylate CEP has been issued for it. The manufacturer submits a Dabigatran Etexilate Mesylate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Dabigatran Etexilate Mesylate CEP holder for the record. Additionally, the data presented in the Dabigatran Etexilate Mesylate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Dabigatran Etexilate Mesylate DMF.
A Dabigatran Etexilate Mesylate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Dabigatran Etexilate Mesylate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Dabigatran Etexilate Mesylate suppliers with CEP (COS) on PharmaCompass.
A Dabigatran Etexilate Mesylate written confirmation (Dabigatran Etexilate Mesylate WC) is an official document issued by a regulatory agency to a Dabigatran Etexilate Mesylate manufacturer, verifying that the manufacturing facility of a Dabigatran Etexilate Mesylate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Dabigatran Etexilate Mesylate APIs or Dabigatran Etexilate Mesylate finished pharmaceutical products to another nation, regulatory agencies frequently require a Dabigatran Etexilate Mesylate WC (written confirmation) as part of the regulatory process.
click here to find a list of Dabigatran Etexilate Mesylate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Dabigatran Etexilate Mesylate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Dabigatran Etexilate Mesylate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Dabigatran Etexilate Mesylate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Dabigatran Etexilate Mesylate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Dabigatran Etexilate Mesylate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Dabigatran Etexilate Mesylate suppliers with NDC on PharmaCompass.
Dabigatran Etexilate Mesylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dabigatran Etexilate Mesylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dabigatran Etexilate Mesylate GMP manufacturer or Dabigatran Etexilate Mesylate GMP API supplier for your needs.
A Dabigatran Etexilate Mesylate CoA (Certificate of Analysis) is a formal document that attests to Dabigatran Etexilate Mesylate's compliance with Dabigatran Etexilate Mesylate specifications and serves as a tool for batch-level quality control.
Dabigatran Etexilate Mesylate CoA mostly includes findings from lab analyses of a specific batch. For each Dabigatran Etexilate Mesylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dabigatran Etexilate Mesylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Dabigatran Etexilate Mesylate EP), Dabigatran Etexilate Mesylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dabigatran Etexilate Mesylate USP).